--- title: "China approved the world's first implanted brain-computer interface as a medical device" date: 2026-11-08 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-neuracle-neo-nmpa-approval language: en --- # China approved the world's first implanted brain-computer interface as a medical device > Neuracle's NEO-ONE SCI, a hands-assist implant for cervical spinal injury, became the first invasive brain-computer interface to win NMPA Class III registration — a regulatory first with global implications. For most of its history, the brain-computer interface (脑机接口) has lived in two places: research papers and venture-capital decks. That changed in March 2026, when a Chinese regulator did something no major authority had done before — it approved an implanted BCI as a finished medical device. The product is NEO-ONE SCI, made by Neuracle (博睿康), a Shanghai company spun out of Tsinghua University's neuroengineering group. Its registration with China's National Medical Products Administration (NMPA, 国家药监局) as a Class III device is the first time an invasive brain-computer interface has cleared that bar anywhere, according to the company and domestic reporting. ## A regulatory first Class III is the strictest category of medical device in China, reserved for implants and life-supporting products that carry the highest risk. To reach it, NEO-ONE SCI entered NMPA's innovation medical device special review channel (创新医疗器械特别审查) in August 2024, a fast-track for genuinely novel products. According to Neuracle, the device completed 36 clinical surgeries — four early feasibility cases and thirty-two in a multicenter confirmatory study — with final endpoint data collected at the end of November 2025, before registration in March 2026. That sequence, if borne out in public filings, represents one of the more complete clinical journeys any invasive BCI program has published to date. ## What the device does NEO-ONE SCI is built for a specific, heartbreaking population: adults whose cervical spinal cord injury has left them quadriplegic, with fingers that cannot close around an object. The system is a hands-assist compensator. Its implant, about the size of two coins, is fixed with only local bone grinding and communicates wirelessly with an external unit, so there is no battery inside the body to leak or degrade. The deeper idea is a bidirectional closed-loop (双向闭环) design: the system records brain signals, decodes the user's intent, drives an external device such as a glove, and feeds sensation or state information back. Closing that loop is what lets "intent triggers action, action returns feedback" become a repeatable training cycle rather than a one-off trick. ## The clinical evidence behind it Neuracle reports that in its study, every assessed patient showed an ARAT (a standard hand-function scale) response at both three and six months after implantation, and that roughly 68.8 percent of patients achieved a statistically significant improvement in grasp score at six months without assistance. Those numbers, if verified in peer review, would be a concrete benchmark for a field that has mostly shown single-subject demos. The company has also built a substantial non-invasive business. It sells more than twenty neuro-signal products, including a 1024-channel EEG machine that it says received the world's first such NMPA registration in 2020, and claims the top domestic market share in EEG equipment for 2025, used in over five hundred medical institutions. That installed base is part of why a small neurotech firm could staff and fund an invasive clinical program at all. ## Why this matters beyond China Regulatory approval is the gate that turns a promising prototype into something a doctor can actually prescribe. Until now, every invasive BCI in humans — whether from academic groups or companies like Neuralink — has been experimental, sitting outside routine clinical use. A Class III registration creates a framework other regulators can study, and a reimbursement and training pathway inside Chinese hospitals. It also reframes the competitive map. For years the public story of implanted BCI was dominated by a few high-profile Western names. Neuracle's registration shows that China's neurotech sector is not only producing research but shipping regulated, implantable product. ## Key takeaways - Neuracle's NEO-ONE SCI became the first invasive BCI to receive NMPA Class III registration, in March 2026. - It is designed for quadriplegic adults with cervical spinal injury who cannot grasp objects. - The system uses a battery-free, wireless implant and a bidirectional closed-loop (双向闭环) design. - Neuracle reports 36 surgeries and meaningful hand-function gains in its study, pending broader verification. - Approval creates a clinical, regulatory, and reimbursement pathway absent for experimental implants elsewhere. ## What readers can do now - **Track real-world use, not just the certificate:** Approval is necessary but not sufficient; watch for how many patients are actually implanted in hospitals post-registration. - **Read the fine print on indication:** This device targets a narrow group (cervical-injury quadriplegia), not general paralysis or speech loss. - **Watch for peer-reviewed evidence:** Ask whether the 68.8 percent hand-function figure appears in a journal with full methods. ## Honest limitations This article draws on Neuracle's official company disclosures and Chinese media reporting of the March 2026 registration; at the time of writing we did not locate an independent peer-reviewed publication of the pivotal trial's full dataset. The 36-surgery count and the 68.8 percent six-month improvement figure are the company's reported outcomes and have not been re-audited here against raw clinical records. The "world's first invasive BCI medical device" claim is presented by the company and domestic outlets; we could not independently confirm that no other jurisdiction had approved a comparable implant earlier. As with all implantable neurotech, long-term biocompatibility, battery-free power reliability, and durable functional benefit require continued post-market follow-up. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-neuracle-neo-nmpa-approval Free to quote with attribution and a link to the original.